A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma
Public ClinicalTrials.gov record NCT02783599. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b Trial to Assess the Modulation of Biological Markers in Patients With Potentially Resectable Soft Tissue Sarcoma Treated With Olaratumab Monotherapy Followed by Olaratumab Plus Doxorubicin Combination Therapy
Study identification
- NCT ID
- NCT02783599
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Eli Lilly and Company
- Industry
- Enrollment
- 51 participants
Conditions and interventions
Conditions
Interventions
- Olaratumab Drug
- Doxorubicin Drug
- External Beam Radiotherapy Radiation
Drug · Radiation
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 10, 2016
- Primary completion
- Jul 4, 2018
- Completion
- Jul 4, 2018
- Last update posted
- Aug 11, 2019
2016 – 2018
United States locations
- U.S. sites
- 9
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| USC/Norris Comp Cancer Center | Los Angeles | California | 90033 | — |
| Yale University School of Medicine | New Haven | Connecticut | 06520 | — |
| All Children's Hospital | St. Petersburg | Florida | 33701 | — |
| Moffitt Cancer Center & Research Inst | Tampa | Florida | 33612 | — |
| Kansas City Cancer Center | Overland Park | Kansas | 66210 | — |
| Washington University Medical Center | St Louis | Missouri | 63110 | — |
| Levine Children's Hospital | Charlotte | North Carolina | 28203 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | — |
| Mary Crowley Cancer Research | Dallas | Texas | 75230 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02783599, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 11, 2019 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02783599 live on ClinicalTrials.gov.